| Drug General Information |
| Drug ID |
D0GZ7B
|
| Former ID |
DNC000170
|
| Drug Name |
AG490
|
| Drug Type |
Small molecular drug
|
| Indication |
Renal transplantation; Multiple myeloma [ICD9: 279.5, 203; ICD10:D89.8, C90]
|
Terminated |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H14N2O3
|
| InChI |
InChI=1S/C17H14N2O3/c18-10-14(8-13-6-7-15(20)16(21)9-13)17(22)19-11-12-4-2-1-3-5-12/h1-9,20-21H,11H2,(H,19,22)/b14-8+
|
| InChIKey |
TUCIOBMMDDOEMM-RIYZIHGNSA-N
|
| CAS Number |
CAS 133550-30-8
|
| PubChem Compound ID |
|
| PubChem Substance ID |
629517, 8033990, 11061045, 11111876, 11113487, 14849288, 17405722, 24278732, 26751707, 26751708, 26759681, 39301404, 47290860, 47588720, 47810470, 47810471, 47885126, 48110172, 50104393, 50104394, 50104395, 53778272, 53789794, 56314167, 56463448, 57361285, 71751762, 78726229, 80953720, 85231253, 85787739, 88804259, 90341519, 92303385, 92309812, 99300726, 99302244, 99302805, 99436917, 103244043, 104051609, 113910669, 118311117, 124658725, 124757030, 124799933, 124881621, 124881622, 124881623, 124881624
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase JAK2 |
Target Info |
Inhibitor |
[3]
|
|---|
| Tyrosine-protein kinase JAK3 |
Target Info |
Inhibitor |
[4]
|
|
KEGG Pathway
|
Chemokine signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Jak-STAT signaling pathway
|
|
Cholinergic synapse
|
|
Prolactin signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Leishmaniasis
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Measles
|
|
Influenza A
|
|
Herpes simplex infectionhsa04062:Chemokine signaling pathway
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
Primary immunodeficiency
|
|
PANTHER Pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interferon-gamma signaling pathway
|
|
JAK/STAT signaling pathway
|
|
PDGF signaling pathway
|
|
PI3 kinase pathway
|
|
CCKR signaling map STP00036:Interleukin signaling pathway
|
|
Pathway Interaction Database
|
Endothelins
|
|
ErbB4 signaling events
|
|
GMCSF-mediated signaling events
|
|
IL4-mediated signaling events
|
|
IL27-mediated signaling events
|
|
Signaling events mediated by PTP1B
|
|
IL12-mediated signaling events
|
|
S1P3 pathway
|
|
SHP2 signaling
|
|
CXCR4-mediated signaling events
|
|
IL5-mediated signaling events
|
|
IFN-gamma pathway
|
|
ErbB2/ErbB3 signaling events
|
|
IL3-mediated signaling events
|
|
IL6-mediated signaling events
|
|
PDGFR-beta signaling pathway
|
|
IL23-mediated signaling events
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
EPO signaling pathway
|
|
Notch-mediated HES/HEY networkil4_2pathway:IL4-mediated signaling events
|
|
CD40/CD40L signaling
|
|
Signaling events mediated by TCPTP
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IL2 signaling events mediated by STAT5
|
|
Reactome
|
Interleukin-6 signaling
|
|
MAPK3 (ERK1) activation
|
|
MAPK1 (ERK2) activation
|
|
GPVI-mediated activation cascade
|
|
Prolactin receptor signaling
|
|
RMTs methylate histone arginines
|
|
G beta:gamma signalling through PI3Kgamma
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
RAF activation
|
|
RAF/MAP kinase cascade
|
|
Interferon gamma signaling
|
|
Regulation of IFNG signaling
|
|
Interleukin receptor SHC signaling
|
|
Growth hormone receptor signaling
|
|
Factors involved in megakaryocyte development and platelet productionR-HSA-114604:GPVI-mediated activation cascade
|
|
Interleukin-7 signaling
|
|
Interleukin-2 signaling
|
|
WikiPathways
|
Serotonin Receptor 2 and STAT3 Signaling
|
|
Type II interferon signaling (IFNG)
|
|
Notch Signaling Pathway
|
|
EPO Receptor Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
IL-6 signaling pathway
|
|
Kit receptor signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Mesodermal Commitment Pathway
|
|
Interleukin-2 signaling
|
|
Signaling by SCF-KIT
|
|
Prolactin receptor signaling
|
|
Growth hormone receptor signaling
|
|
JAK/STAT
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
TSLP Signaling Pathway
|
|
IL17 signaling pathway
|
|
Leptin signaling pathway
|
|
TSH signaling pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
Interferon gamma signaling
|
|
Factors involved in megakaryocyte development and platelet production
|
|
IL-5 Signaling PathwayWP49:IL-2 Signaling Pathway
|
|
Interleukin-7 signaling
|
|
IL-9 Signaling Pathway
|
|
IL-7 Signaling Pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5916). |
|---|
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006610) |
|---|
| REF 3 | Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. J Biol Chem. 2004 Aug 13;279(33):34547-52. Epub 2004 May 24. |
|---|
| REF 4 | Immunotherapy for De Novo renal transplantation: what's in the pipeline? Drugs. 2006;66(13):1665-84. |
|---|
